Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lasofoxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 17/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 9/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | NPY1R | P25929 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lasofoxifene SCHEMBL5727524 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL30170471 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL117914 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL30170470 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL117915 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL3774592 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL3774585 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL29454456 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL9885582 | 1.00 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Lasofoxifene SCHEMBL3771361 | 0.99 | ESR1 (1.00) | ESR1ESR2MLNRNR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12019 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2026086804-A1 | MULTILAYER-REGULATED GENE EDITING SYSTEM AND USE THEREOF | 自如基因科技（深圳）有限公司 | 2026-04-30 | — | — | WO | claimed |
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | claimed |
| EP-4719405-A1 | METHODS AND MODIFIED DOSING REGIMENS COMPRISING A CDK4 INHIBITOR FOR THE TREATMENT OF CANCER | Pfizer Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4712963-A2 | SMALL MOLECULE INHIBITORS OF P27 | Concarlo Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260028309-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | RADIUS PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| EP-0876359-A1 | (-) CIS-6(S)-PHENYL-5(R) 4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]-5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL D-TARTRATE | PFIZER INC. (US) | 1998-11-11 | — | — | EP | claimed |
| EP-0842661-A2 | Atherosclerosis treatment | PFIZER INC. (US) | 1998-05-20 | — | — | EP | claimed |
| EP-0802910-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER INC. (US) | 1997-10-29 | — | — | EP | claimed |
| WO-1997031640-A1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER INC. (US) | 1997-09-04 | — | — | WO | claimed |
| EP-0792645-A1 | Combination therapy to treat osteoporosis | PFIZER INC. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0792641-A1 | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions | PFIZER INC. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0792642-A1 | Method of treating conditions with estrogen agonists | PFIZER INC. (US) | 1997-09-03 | — | — | EP | claimed |
| WO-1997016434-A1 | (-) CIS-6(S)-PHENYL-5(R)[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]-5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL D-TARTRATE | PFIZER INC. (US) | 1997-05-09 | — | — | WO | claimed |
| US-5552412-A | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis | PFIZER INC (US) | 1996-09-03 | — | — | US | claimed |
| WO-1996021656-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER, INC. (US) | 1996-07-18 | — | — | WO | claimed |